Edge Therapeutics Inc., of Berkeley Heights, N.J. reported that its ongoing phase I/I study of the company's lead candidate, EG-1962 for patients that have suffered a subarachnoid hemorrhage from a ruptured brain aneurysm, has completed enrollment and yielded safety and 90-day functional outcome efficacy data for 24 patients.